Retinal Morpho-functional Evaluation of Patients Affected by Inherited Retinal Dystrophies (NEU 02-25)

November 11, 2026 updated by: Fondazione G.B. Bietti, IRCCS

The present study aims to perform a detailed morpho-anatomical and electro-functional characterization of patients affected by IRD, to investigate on the features of specific retinal layers (outer and inner) and to identify the functional involvement of macular elements located in specific areas. Through a systematic approach to anatomical and functional pattern classifications, this study seeks to refine the phenotypic understanding of IRD and to contribute to a deeper comprehension of its pathophysiological underpinnings, for exploring whether subretinal factors are involving in the etiopathogenesis.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This single-center retrospective observational study evaluates retinal structure and function in patients with clinically confirmed inherited retinal dystrophies. Patients are identified consecutively from those evaluated between 2015 and August 31, 2025. After written informed consent is obtained, demographic and clinical data are extracted from existing records, together with results from a single previously completed ophthalmic visit (Visit 1). The data include medical history, best-corrected visual acuity, anterior and posterior segment examination, intraocular pressure, spectral-domain optical coherence tomography, optical coherence tomography angiography, multifocal electroretinography, multifocal photopic negative response recordings, visual field testing, and documented ocular complications related to inherited retinal dystrophies.

Study Type

Observational

Enrollment (Estimated)

18

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients aged 18 to 90 years with clinically confirmed inherited retinal dystrophies who were evaluated at the study center between 2015 and August 31, 2025, and have the clinical and instrumental records required by the protocol.

Description

Inclusion Criteria:

  • Patients with clinically confirmed inherited retinal dystrophy
  • Age between 18 and 90 years
  • Male or female patients
  • Available recordings of mfERG and mfPhNR, SD-OCT and OCT-A, Visual Acuity (BCVA) and Visual Field (VF)
  • Phakic and pseudophakic eyes
  • Informed consent freely granted and acquired before data collection

Exclusion Criteria:

  • Patients underwent cataract surgery 6 months before data acquisition
  • Patients with any other ophthalmological diseases affecting cornea, lens, optic nerve and acquired retinal diseases (i.e. central serous chorioretinopathy, retinal vein occlusion, age-related macular degeneration) at the time of data acquisition
  • Patients with diabetes and\or any other systemic condition affecting the macular function and structure
  • Patients who underwent to macular laser procedures before data acquisition
  • Concomitant treatment with any systemic or ocular drug influencing macular structure and function at the time of data acquisition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Patients with inherited retinal dystrophies

Patients with clinically confirmed inherited retinal dystrophies identified consecutively from those evaluated at the study center between 2015 and August 31, 2025

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Central Retinal Thickness Measured by SD-OCT
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Central retinal thickness, in micrometers (µm), measured by spectral-domain optical coherence tomography (SD-OCT).

At a single previously completed ophthalmic visit (Visit 1).
Ring 1 Response Amplitude Density Measured by Multifocal Electroretinography
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Response amplitude density, in nV/deg², measured by multifocal electroretinography (mfERG) in the innermost fovea-centered ring (R1).

At a single previously completed ophthalmic visit (Visit 1).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Best-Corrected Visual Acuity
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Mean best-corrected visual acuity, expressed in logMAR.

At a single previously completed ophthalmic visit (Visit 1).
Multifocal Electroretinography Response Amplitude Density by Macular Ring
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Response amplitude density, in nV/deg², measured by multifocal electroretinography (mfERG) and reported separately for the five fovea-centered rings (R1-R5).

At a single previously completed ophthalmic visit (Visit 1).
Multifocal Photopic Negative Response Amplitude Density by Macular Ring
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Response amplitude density, in nV/deg², measured from multifocal photopic negative response (mfPhNR) recordings and reported separately for the five fovea-centered rings (R1-R5).

At a single previously completed ophthalmic visit (Visit 1).
Mean Perimetric Sensitivity
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Mean perimetric sensitivity derived from visual field testing.

At a single previously completed ophthalmic visit (Visit 1).
Inner and Outer Retinal Layer Thickness by Macular Region
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Thickness of the inner and outer retinal layers, in micrometers (µm), measured by SD-OCT in localized macular regions defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) map.

At a single previously completed ophthalmic visit (Visit 1).
Macular Vessel Density Measured by OCT Angiography
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Vessel density measured by optical coherence tomography angiography (OCT-A) in localized macular regions and reported separately for the superficial capillary plexus, deep capillary plexus, and choriocapillaris.

At a single previously completed ophthalmic visit (Visit 1).
Inherited Retinal Dystrophy-Related Ocular Complications
Time Frame: At a single previously completed ophthalmic visit (Visit 1).

Ocular complications documented in patients with inherited retinal dystrophies, including macular edema and cataract.

At a single previously completed ophthalmic visit (Visit 1).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Lucia Ziccardi, Professor, IRCCS Fondazione G. B. Bietti

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2025

Primary Completion (Actual)

December 10, 2025

Study Completion (Estimated)

October 21, 2036

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NEU 02-25
  • NEU 02-25 (N. 408/FB/25) (Other Identifier: IRCCS Fondazione Bietti ETS)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The individual participant data (IPD) that will be eventually shared are retinal morpho-functional evaluation of patients affected by inherited retinal dystrophies (OCT; OCT-A, mfERG, mfPhNR data), visual field, visual acuity, ocular complications related to IRDs.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.